What Atrium Therapeutics does

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision RNA medicines for rare genetic cardiomyopathies. The company was established February 27, 2026 as an independent publicly traded entity on Nasdaq (ticker: RNA), spun off from Avidity Biosciences following Novartis AG's approximately $12 billion acquisition of Avidity. Atrium launched with approximately $270 million in cash and acquired the proprietary AOC (Antibody-Oligonucleotide Conjugate) RNA delivery platform originally designed at Avidity, which combines monoclonal antibody tissue selectivity with oligonucleotide precision to enable targeted, non-viral siRNA delivery to cardiac tissue, circumventing cytotoxicity, immunogenicity, and redosing limitations that constrain alternative delivery systems.

The company's pipeline is anchored by two lead siRNA candidates: ATR 1072 for PRKAG2 syndrome (IND filing planned H2 2026) and ATR 1086 for PLN cardiomyopathy (IND filing planned 2027), with two additional undisclosed research-stage targets in rare cardiomyopathies. The patient population targeted is small but underserved — approximately 1,000-2,000 US patients for PRKAG2 syndrome and 2,000-4,000 US patients for PLN cardiomyopathy, with no approved disease-modifying therapies currently addressing the underlying genetic drivers of either condition. Atrium's headquarters is in San Diego, California, and the company operates with 11-50 employees under a leadership team and board composed primarily of former Avidity Biosciences executives.

Atrium's business model is anchored by a global licensing and research collaboration with Bristol Myers Squibb (announced April 23, 2026) covering discovery, development, and commercialization of RNA-based cardiovascular therapies. BMS funds all future clinical development, regulatory, and commercialization activities, and Atrium is eligible for up to approximately $1.35 billion in R&D milestones, up to $825 million in commercial milestones, and tiered royalties up to low double-digits on net sales. Q1 2026 collaboration revenue was $19.6 million, primarily a $15 million BMS milestone payment plus R&D services revenue. As a pre-commercial biotech, Atrium does not yet sell any approved products and depends on milestone payments, R&D services fees, and eventual royalties as its revenue streams.

Name

Atrium Therapeutics

Legal name

Atrium Therapeutics, Inc.

Website

https://atriumtherapeutics.com

Company type

Public

Founded year

2026

Operating status

Operating

Headcount range

11–50 employees

Short description

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision siRNA medicines using its proprietary AOC delivery platform to target rare genetic cardiomyopathies (PRKAG2 syndrome and PLN cardiomyopathy), operating primarily through a global licensing and research collaboration with Bristol Myers Squibb.

Ownership category

akta.pro rank

Product category

Precision RNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

akta.pro secondary industries

Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• RNA therapeutics
• Cardiac RNA delivery
• SiRNA drug development
• Rare cardiomyopathy treatments
• Antibody-oligonucleotide conjugates

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Collaboration/Partnership Revenue: Atrium earns milestone payments and royalties through its global licensing and research collaboration with Bristol Myers Squibb for RNA-based cardiovascular therapies. The company is eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales.
2. R&D Services Revenue: Revenue generated from research and development services provided under collaboration agreements, including delivery of development candidates. Q1 2026 included $19.6 million in collaboration revenue, with $15 million from BMS milestone payment and remainder from R&D services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision RNA therapeutics for rare genetic cardiomyopathies using its proprietary antibody-oligonucleotide conjugate (AOC) delivery platform. Its lead pipeline candidates are ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both siRNA therapies designed to address the underlying genetic drivers of these life-threatening cardiac conditions. The company partnered with Bristol Myers Squibb for global clinical development and commercialization under a deal worth up to approximately $2.175 billion in milestones plus royalties.

Product overview

Atrium Therapeutics is a biopharmaceutical company pioneering targeted delivery of RNA therapeutics to the heart for precision cardiology. The company operates a platform-plus-pipeline model, with its proprietary AOC (antibody-oligonucleotide conjugate) RNA delivery platform as the core technology enabling the development of multiple therapeutic candidates. The lead pipeline candidates are ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both siRNA-based therapies targeting the underlying genetic drivers of rare cardiomyopathies. The company also has two undisclosed research-stage targets in rare cardiomyopathies.

Differentiator

Problem solved

Functional benefit

Products and services

• ATR 1072 siRNA therapeutic candidate for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome that works through sequence-specific gene silencing to reduce PRKAG2 mRNA, normalize AMPK activity, and reduce pathogenic glycogen accumulation in cardiac muscle cells, with the goal of improving heart function in patients with this rare genetic cardiomyopathy.
• ATR 1086 Therapeutic candidate for PLN (phospholamban) cardiomyopathy designed to address the underlying genetic driver of disease by reducing PLN expression in cardiac muscle, relieving SERCA2a inhibition, and restoring calcium cycling dynamics.

Quantifiable outcome

• Up to approximately $1.35 billion in R&D milestone payments plus up to $825 million in commercial milestone payments plus tiered royalties up to low double-digits on net sales from BMS collaboration
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Bristol Myers SquibbcoreStrategic or Co-development Partner · 23 April 2026Global licensing and research collaboration focused on discovery, development and commercialization of innovative RNA-based therapies for multiple cardiovascular indications. Atrium is eligible to receive up to approximately $1.35 billion in R&D milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. Bristol Myers Squibb will fund all future clinical development, regulatory and commercialization activities coming from the collaboration. The milestone payment of $15 million was achieved upon successful delivery of a development candidate for the first licensed compound targeting a cardiology indication.
• Avidity BiosciencescoreTechnology or Integration · 27 February 2026Spin-off relationship from Novartis AG's acquisition of Avidity Biosciences. Atrium acquired the targeted RNA delivery platform (AOC technology) originally designed at Avidity, along with early-stage precision cardiology programs (ATR 1072 and ATR 1086) and approximately $270 million in cash. The proprietary AOC technology combines the tissue selectivity of monoclonal antibodies and other targeted delivery ligands with the precision of oligonucleotides for targeted siRNA delivery to cardiac tissues.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Avidity Biosciences: Original developer of the AOC platform that Atrium was built around and spun out from. Directly comparable RNA therapeutics platform company with antibody-oligonucleotide conjugate technology targeting muscle and other tissues; recently acquired by Novartis for ~$12B.
• Wave Life Sciences: Clinical-stage RNA therapeutics company focused on rare genetic diseases using stereopure oligonucleotide platform. Comparable modality (oligonucleotide-based) and similar pipeline-stage economics, though with different delivery technology.
• Ionis Pharmaceuticals: Leading RNA-targeted therapeutics company and parent lineage of Atrium's COO and several board members (Akcea). Pioneered antisense oligonucleotide technology and many rare disease programs; a direct comparable given similar RNA modality focus and rare disease commercialization expertise.
• Cytokinetics: Cardiology-focused specialty biotech developing cardiac myosin modulators for HCM and other cardiomyopathies. Directly comparable target patient population (HCM, PLN/RBM20 carriers) and overlapping cardiology pipeline ambition.
• Tenaya Therapeutics: Genetic cardiomyopathy-focused biotech developing AAV gene therapies for HCM, DCM and other rare cardiac indications. Directly comparable precision-cardiology strategy targeting genetic drivers of cardiomyopathies using a different modality (gene therapy).
• Alnylam Pharmaceuticals: Established siRNA therapeutics leader with approved RNAi drugs (Onpattro, Givlaari, Oxlumo, Amvuttra). Directly comparable RNA modality platform serving rare and cardiometabolic indications; defines the commercial RNA therapeutics benchmark.
• Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with proprietary siRNA delivery technology and broad pipeline including cardiovascular programs. Comparable RNAi platform approach and cardiac indication ambition.

Emerging players

• Lexeo Therapeutics: Cardiology gene therapy biotech with programs targeting cardiomyopathies including PLN-related disease. Comparable genetic cardiology focus and parallel therapeutic pursuit of PLN cardiomyopathy, providing a competitive cross-reference.
• Cardurion Pharmaceuticals: Cardiovascular-focused clinical-stage biotech developing kinase and PDE inhibitors for heart failure and rare cardiomyopathies. Comparable focus on genetic and rare cardiac disease drug development though small-molecule modality.

Broad incumbents

• BridgeBio Pharma: Broader rare genetic disease drug developer with cardiovascular programs including attruby (acoramidis) for ATTR-CM. Comparable genetic cardiology/rare disease focus and similar partnership-driven development model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/atrium-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atrium Therapeutics